• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Open Science

The Alliance expects all research collaborators to make their outputs (materials and knowledge) publicly available, without restriction on use, and to follow the values, principles, and practices in this Open Science Statement. They support the Alliance’s own values on open science.

The table below shows how the values, principles, and practices connect. The numbered practices that follow explain each commitment in more detail.

On this page

Values, principles, and practices  │  Open science practices

Values, principles, and practices

Open Science Statement: values, principles, and practices
Values Principles Practices
Human-centric Fairness Representative; respectful
Inclusive Communications; behaviours; driven by people living with ALS/MND and their communities (PALS/CALS)
Accountability Intellectual property (IP); auditable
Knowledge-sharing Urgency Timely
Transparency Article access
Interoperable Data and code access
Replicable and reproducible Protocols
Trustworthy Reliability Accessible documentation
Private and secure Compliance processes and guidelines
Follow-on research Re-use; attribution and acknowledgement

Practices

  1. Each researcher or project will have a plan for how the principles of open science will be followed, from the start of the project to its end. The plan will describe how the values of human-centric, knowledge-sharing, and trustworthy research will be met.
  2. Where possible, existing human data will be used, so that people living with ALS/MND and their communities do not have to undergo repeat testing if they have given informed consent for their data to be made available under open science principles.
  3. Researchers will post experimental protocols to a protocol-sharing service, such as protocols.io.
  4. All articles resulting from funding must be published in a fully open access journal or posted in an open repository with free, immediate readership rights.
  5. Researchers will seek to place open access results arising from research projects (internal or collaborative) in the public domain. In any Alliance project they undertake (internal or collaborative), researchers will not file any form of patent application or allow a collaborator to restrict the research use of open access project outputs.
  6. Data will be shared according to the FAIR principles: Findability, Accessibility, Interoperability, and Reuse of digital assets.
  7. Researchers will promptly release the associated output data through free and publicly accessible digital repositories, while continuing to comply with all applicable privacy and confidentiality regulations.
  8. Any data, code, and software needed for independent verification of research results must be curated and made freely and publicly available in an established, open repository. This must happen no later than the publication of the first paper based on the data or the end of the grant, whichever comes first.
  9. Research outputs (articles, data, code, and software) resulting from funding must be made available with broad reuse and remixing rights (for example, CC BY or CC0 licences).
  10. Applicants will be encouraged to include the anticipated costs of making their work open in their grant applications.
  11. All researchers and projects will include a data-sharing plan as part of the application process. Compliance checkpoints throughout the term of engagement will proactively collect proof of compliance with this policy, as part of interim and final reports.

Primary Sidebar

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Jon Newsome, USA

    Jon Newsome, USA

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Angelique van der Lit-van Veldhuizen, Netherlands

    Angelique van der Lit-van Veldhuizen, Netherlands

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Bob Simonds, USA

    Bob Simonds, USA

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Ian Gale, Australia

    Ian Gale, Australia

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Paul Launer, USA

    Paul Launer, USA

  • Eddy LeFrançois, Canada

    Eddy LeFrançois, Canada

  • Hanne Stenmose, Denmark

    Hanne Stenmose, Denmark

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Debbie Craghill, USA

    Debbie Craghill, USA

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Bayley, Australia

    Bayley, Australia

  • Frank Taylor, USA

    Frank Taylor, USA

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • H. Todd Kelly, USA

    H. Todd Kelly, USA

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Orlando Ruiz, Colombia

    Orlando Ruiz, Colombia

  • Daniel Hare, USA

    Daniel Hare, USA

  • Andrew Langat, Kenya

    Andrew Langat, Kenya

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Zabun Nassar, England

    Zabun Nassar, England

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Ali Var, Turkey

    Ali Var, Turkey

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Liong Ting Ngu, Malaysia

    Liong Ting Ngu, Malaysia

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login